CK Life Sciences establishes Scientific Advisory Board

CK Life Sciences (0775) announced on Tuesday the establishment of its Scientific Advisory Board, a strategic body of independent experts from academia, clinical research, and industry, aiming to accelerate its advancement of innovative therapies.
 
The SAB will provide high-level scientific, clinical, and regulatory guidance to support the company’s rapidly advancing research and development pipeline, including multiple therapeutic cancer vaccine candidates approaching clinical readiness, the company said.

The new board will serve as an expert external resource to help the company navigate the increasingly complex landscape of global drug development, mitigate key risks, and accelerate pathways toward regulatory approval and patient access, it added.

CK Life Sciences appointed Dr Ko Wing-man, a respected public health leader in Hong Kong, as the chairman of the SAB to guide the board’s discussions and ensure that expert insights are translated into strategic recommendations for the company.  

The board members also include Rina Hui Yee-man, clinical professor and director of the Centre of Cancer Medicine at the University of Hong Kong, Tony Mok Shu-kam, the Li Shu Fan professor and chairman of Clinical Oncology at The Chinese University of Hong Kong, Damian O’Connell, chief executive of Singapore’s Experimental Drug Development Centre under the Agency for Science, Technology and 
Research, Craig L. Slingluff Jr., a surgical oncologist and leading melanoma immunologist at the University of Virginia, Kenneth G.C. Smith, the Director of the Walter and Eliza Hall Institute in Australia, and formerly Head of the Department of Medicine at the University of Cambridge.

"The members of our SAB bring world-class expertise, and their guidance will help us accelerate the development of innovative therapies with the potential to transform patient care,” said deputy chairman Alan Abel Yu Ying-choi.

Ko said CK Life Sciences is pursuing an ambitious scientific agenda with strong potential to address unmet medical needs, and he looks forward to working with fellow board members to provide independent expert advice that supports rigorous development and responsible innovation.